SUT
QNCX icon

SC US (TTGP)’s Quince Therapeutics QNCX Stock Holding History

SC US (TTGP)’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,803
Closed -$29.7M – 16
2021
Q2 		$29.7M Sell
2,803
-2,399
-46% -$20.1M 0.19% 12
2021
Q1 		$37.5M Hold
5,202
– – 0.22% 10
2020
Q4 		$28.9M Hold
5,202
– – 0.17% 11
2020
Q3 		$52M Hold
5,202
– – 0.5% 9
2020
Q2 		$48.2M Hold
5,202
– – 2.83% 4
2020
Q1 		$47.5M Hold
5,202
– – 3.64% 5
2019
Q4 		$58.4M Hold
5,202
– – 2.51% 8
2019
Q3 		$25.9M Hold
5,202
– – 1.15% 9
2019
Q2 		$44.2M Buy
+5,202
New +$31.1M 3.02% 8

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SC US (TTGP)'s QNCX Position: Q3 2021 in Review

SC US (TTGP) sold out of Quince Therapeutics (QNCX) in Q3 2021, closing a stake of 2,803 shares — an estimated $29.7M sold.

SC US (TTGP) first reported a position in QNCX in Q2 2019 and held it in 9 quarters. The position peaked at $58.4M in Q4 2019. 126 funds tracked by Wall St. Rank hold QNCX as of Q3 2021.

  • SC US (TTGP) reported no remaining Quince Therapeutics position as of Q3 2021 after selling out during the quarter.
  • SC US (TTGP) sold 2,803 Quince Therapeutics shares in Q3 2021, an estimated $29.7M.
  • SC US (TTGP) first reported a position in Quince Therapeutics in Q2 2019 and held it in 9 quarters.
  • SC US (TTGP)'s Quince Therapeutics position peaked at $58.4M in Q4 2019.
  • 126 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2021.

Based on SC US (TTGP)'s 13F filing for Q3 2021, filed 15 Nov 2021.